United Kingdom-based AstraZeneca has revealed three-year overall survival results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, it was reported yesterday.

These latest results reveal a durable and sustained overall survival benefit in patients with unresectable, Stage III non-small cell lung cancer who had not progressed following concurrent chemoradiation therapy, a previous standard-of-care treatment. The overall survival rate was 57% at three years for patients receiving Imfinzi vs 43.5% for placebo following concurrent CRT. Median OS was not yet reached with the Imfinzi arm vs 29.1 months for placebo.

Dave Fredrickson, executive vice president, Oncology Business Unit said, 'These findings for Imfinzi are another example of our focus on bringing long-term survival benefits to patients who still have a chance of being cured. These three-year survival results further establish the PACIFIC regimen as the standard of care for these patients, and we are optimistic this survival trend will continue as we move towards the five-year landmark in this curative-intent setting.'

AstraZeneca has several ongoing trials focused on testing Imfinzi in earlier stages of NSCLC (Stages I-III) in potentially-curative settings.